Large‐scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: A hallmark of Alzheimer's disease (AD) is the aggregation of proteins (amyloid beta [A] and hyperphosphorylated tau [T]) in the brain, making cerebrospinal fluid (CSF) proteins of particular interest. METHODS: We conducted a CSF proteome‐wide analysis among participants of varying AT pathology (n = 137 participants; 915 proteins) with nine CSF biomarkers of neurodegeneration and neuroinflammation. RESULTS: We identified 61 proteins significantly associated with the AT category (P < 5.46 × 10−5) and 636 significant protein‐biomarker associations (P < 6.07 × 10−6). Proteins from glucose and carbon metabolism pathways were enriched among amyloid‐ and tau‐associated proteins, including malate dehydrogenase and aldolase A, whose associations with tau were replicated in an independent cohort (n = 717). CSF metabolomics identified and replicated an association of succinylcarnitine with phosphorylated tau and other biomarkers. DISCUSSION: These results implicate glucose and carbon metabolic dysregulation and increased CSF succinylcarnitine levels with amyloid and tau pathology in AD. Highlights: Cerebrospinal fluid (CSF) proteome enriched for extracellular, neuronal, immune, and protein processing. Glucose/carbon metabolic pathways enriched among amyloid/tau‐associated proteins. Key glucose/carbon metabolism protein associations independently replicated. CSF proteome outperformed other omics data in predicting amyloid/tau positivity. CSF metabolomics identified and replicated a succinylcarnitine–phosphorylated tau association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationUniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
O'Leary, N. A., Wright, M. W., Brister, J. R., Ciufo, S., Haddad, D., McVeigh, R., Rajput, B., Robbertse, B., Smith-White, B., Ako-Adjei, D., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1189 · Cited by 6,357
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231
Next-generation genotype imputation service and methods
Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., Vrieze, S. I., Chew, E. Y., Levy, S., McGue, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3656 · Cited by 3,808 · cited 1×
“Measurements with the following immunoassays were performed on a cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland): Elecsys β-amyloid (1-42) CSF (Aβ42), Elecsys Phospho-Tau (181P) CSF (phosphorylated tau [p-tau]), and Elecsys Total-Tau CSF, β-amyloid (1-40) CSF (Aβ40), and interleukin-6…”
MethodThe Gene Ontology resource: enriching a GOld mine
The Gene Ontology Consortium, Carbon, S., Douglass, E., Good, B. M., Unni, D. R., Harris, N. L., Mungall, C. J., Basu, S., Chisholm, R. L., Dodson, R. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1113 · Cited by 3,555
HMDB 4.0: the human metabolome database for 2018
Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1089 · Cited by 3,438
A reference panel of 64,976 haplotypes for genotype imputation
the Haplotype Reference Consortium (2016) · Nature Genetics · doi:10.1038/ng.3643 · Cited by 2,836
The DisGeNET knowledge platform for disease genomics: 2019 update
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1021 · Cited by 2,639
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Measurements with the following immunoassays were performed on a cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland): Elecsys β-amyloid (1-42) CSF (Aβ42), Elecsys Phospho-Tau (181P) CSF (phosphorylated tau [p-tau]), and Elecsys Total-Tau CSF, β-amyloid (1-40) CSF (Aβ40), and interleukin-6…”
MethodSelf-citationAptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Reference-based phasing using the Haplotype Reference Consortium panel
Loh, P.-R., Danecek, P., Palamara, P. F., Fuchsberger, C., A Reshef, Y., K Finucane, H., Schoenherr, S., Forer, L., McCarthy, S., Abecasis, G. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3679 · Cited by 1,723
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Integrative omics for health and disease
Karczewski, K. J., & Snyder, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2018.4 · Cited by 1,158
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001 · cited 1×
“Measurements with the following immunoassays were performed on a cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland): Elecsys β-amyloid (1-42) CSF (Aβ42), Elecsys Phospho-Tau (181P) CSF (phosphorylated tau [p-tau]), and Elecsys Total-Tau CSF, β-amyloid (1-40) CSF (Aβ40), and interleukin-6…”
MethodFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Self-citationDeep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression
Bai, B., Wang, X., Li, Y., Chen, P.-C., Yu, K., Dey, K. K., Yarbro, J. M., Han, X., Lutz, B. M., Rao, S., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.015 · Cited by 565
Trushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438 · cited 22×
“Thresholds for p-tau181 were determined by establishing a reference group of 223 CSF amyloid (Aβ42/Aβ40) negative, CU younger participants (ages 40–60 years).”
BackgroundMethodInfluentialHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
Human serum metabolic profiles are age dependent
Yu, Z., Zhai, G., Singmann, P., He, Y., Xu, T., Prehn, C., Römisch‐Margl, W., Lattka, E., Gieger, C., Soranzo, N., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00865.x · Cited by 340
Yang, C., Farias, F. H. G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M. V., Wang, F., Bradley, J. L., Eiffert, B., Bahena, J. A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00886-6 · Cited by 290
Self-citationBosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk
Deming, Y., Filipello, F., Cignarella, F., Cantoni, C., Hsu, S., Mikesell, R., Li, Z., Del-Aguila, J. L., Dube, U., Farias, F. G., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau2291 · Cited by 271
Self-citationMultiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., Stomrud, E., Lee, J., Fitz, L., Samad, T. A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0795-2 · Cited by 262 · cited 1×
“Measurements with the following immunoassays were performed on a cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland): Elecsys β-amyloid (1-42) CSF (Aβ42), Elecsys Phospho-Tau (181P) CSF (phosphorylated tau [p-tau]), and Elecsys Total-Tau CSF, β-amyloid (1-40) CSF (Aβ40), and interleukin-6…”
MethodWang, H., Dey, K. K., Chen, P.-C., Li, Y., Niu, M., Cho, J.-H., Wang, X., Bai, B., Jiao, Y., Chepyala, S. R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00384-6 · Cited by 243
Synergistic insights into human health from aptamer- and antibody-based proteomic profiling
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Kerrison, N. D., Oerton, E., Koprulu, M., Luan, J., Hingorani, A. D., Williams, S. A., Wareham, N. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27164-0 · Cited by 234
Comparison of Proteomic Assessment Methods in Multiple Cohort Studies
Raffield, L. M., Dang, H., Pratte, K. A., Jacobson, S., Gillenwater, L. A., Ampleford, E., Barjaktarevic, I., Basta, P., Clish, C. B., Comellas, A. P., et al. (2020) · PROTEOMICS · doi:10.1002/pmic.201900278 · Cited by 184
Horgusluoglu, E., Neff, R., Song, W., Wang, M., Wang, Q., Arnold, M., Krumsiek, J., Galindo‐Prieto, B., Ming, C., Nho, K., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12468 · Cited by 175
Zhang, Q., Ma, C., Gearing, M., Wang, P. G., Chin, L.-S., & Li, L. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0524-2 · Cited by 165
Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161 · cited 1×
“Measurements with the following immunoassays were performed on a cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland): Elecsys β-amyloid (1-42) CSF (Aβ42), Elecsys Phospho-Tau (181P) CSF (phosphorylated tau [p-tau]), and Elecsys Total-Tau CSF, β-amyloid (1-40) CSF (Aβ40), and interleukin-6…”
MethodLate-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles
Sonntag, K.-C., Ryu, W.-I., Amirault, K. M., Healy, R. A., Siegel, A. J., McPhie, D. L., Forester, B., & Cohen, B. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14420-x · Cited by 131
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126 · cited 1×
“Measurements with the following immunoassays were performed on a cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland): Elecsys β-amyloid (1-42) CSF (Aβ42), Elecsys Phospho-Tau (181P) CSF (phosphorylated tau [p-tau]), and Elecsys Total-Tau CSF, β-amyloid (1-40) CSF (Aβ40), and interleukin-6…”
MethodAlzheimer disease pathology and the cerebrospinal fluid proteome
Dayon, L., Núñez Galindo, A., Wojcik, J., Cominetti, O., Corthésy, J., Oikonomidi, A., Henry, H., Kussmann, M., Migliavacca, E., Severin, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0397-4 · Cited by 101
Ramirez, A., van der Flier, W. M., Herold, C., Ramonet, D., Heilmann, S., Lewczuk, P., Popp, J., Lacour, A., Drichel, D., Louwersheimer, E., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu372 · Cited by 60
Self-citationThe pleiotropic roles of autophagy in Alzheimer’s disease: From pathophysiology to therapy
Festa, B. P., Barbosa, A. D., Rob, M., & Rubinsztein, D. C. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.011 · Cited by 41
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citation
Research works printed but not linked: 57
- 10.1146/annurev‐pathol‐020712‐163927 · DOI · Paper page
- 10.1212/WNL.34.7.939 · DOI · Paper page
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1016/j.jalz.2011.03.008 · DOI · Paper page
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1038/s41588‐019‐0358‐2 · DOI · Paper page
- 10.1038/s41588‐022‐01024‐z · DOI · Paper page
- 10.1016/j.jalz.2010.06.001 · DOI · Paper page
- 10.1371/journal.pone.0150672 · DOI · Paper page
- 10.1038/tp.2016.194 · DOI · Paper page
- 10.1186/1750‐1326‐9‐22 · DOI · Paper page
- 10.1002/prca.202000072 · DOI
- 10.1016/j.dadm.2017.11.007 · DOI · Paper page
- 10.3233/JAD‐150897 · DOI · Paper page
- 10.1016/j.jclinepi.2007.11.008 · DOI · Paper page
- 10.1002/alz.12204 · DOI · Paper page
- MATLAB, Natick
- 10.1177/0272989X9101100204 · DOI · Paper page
- 10.3233/JAD‐160195 · DOI · Paper page
- 10.1002/gepi.22211 · DOI
- 10.1038/s42003‐020‐01583‐z · DOI · Paper page
- 10.1038/nature15393 · DOI · Paper page
- 10.1086/519795 · DOI · Paper page
- 10.1021/acs.analchem.8b02766 · DOI
- 10.1038/nbt.1511 · DOI · Paper page
- 10.1038/nprot.2016.136 · DOI · Paper page
- 10.1093/nar/gky955 · DOI · Paper page
- 10.1093/nar/gkaa980 · DOI · Paper page
- 10.1093/bioinformatics/btw313 · DOI · Paper page
- 10.1093/nar/28.1.27 · DOI · Paper page
- 10.1093/nar/gky1032 · DOI · Paper page
- 10.1089/omi.2011.0118 · DOI · Paper page
- 10.1093/bioinformatics/btu684 · DOI · Paper page
- 10.1039/C5MB00663E · DOI · Paper page
- 10.1016/0020‐0190(89)90102‐6 · DOI · Paper page
- 10.32614/RJ-2016-021 · DOI · Paper page
- GaoC‐H ggVennDiagram: A “ggplot2” Implement of Venn Diagram.2019. · doi:10.32614/cran.package.ggvenndiagram
- 10.1103/PhysRevE.70.066111 · DOI · Paper page
- 10.1212/wnl.43.11.2412‐a · DOI · Paper page
- 10.1212/WNL.0b013e318266fa70 · DOI · Paper page
- 10.1111/j.1467‐9868.2005.00503.x · DOI · Paper page
- 10.18637/jss.v033.i01 · DOI · Paper page
- 10.1111/j.1471‐4159.2009.06558.x · DOI · Paper page
- 10.1080/14789450.2017.1384697 · DOI
- 10.1093/brain/awq035 · DOI · Paper page
- 10.1016/j.jcmgh.2018.04.005 · DOI
- 10.1038/ejhg.2017.96 · DOI
- 10.1186/s13195‐021‐00789‐5 · DOI
- 10.1016/j.celrep.2019.06.073 · DOI · Paper page
- 10.1038/s41380‐021‐01068‐3 · DOI · Paper page
- 10.3233/JAD‐200747 · DOI
- 10.3233/JAD‐151205 · DOI · Paper page
- 10.1007/s12035‐012‐8246‐0 · DOI · Paper page
- 10.1155/2020/5497046 · DOI · Paper page
- 10.1016/j.bbadis.2008.08.012 · DOI
- 10.1016/j.molmet.2020.01.005 · DOI · Paper page
- 10.1007/s11306‐014‐0663‐9 · DOI
Cited by
Miyoshi, E., Morabito, S., Henningfield, C. M., Das, S., Rahimzadeh, N., Shabestari, S. K., Michael, N., Emerson, N., Reese, F., Shi, Z., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01961-x · Cited by 115
Tao, Q.-Q., Cai, X., Xue, Y.-Y., Ge, W., Yue, L., Li, X.-Y., Lin, R.-R., Peng, G.-P., Jiang, W., Li, S., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2023.100544 · Cited by 55
TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation
Moutinho, M., Coronel, I., Tsai, A. P., Di Prisco, G. V., Pennington, T., Atwood, B. K., Puntambekar, S. S., Smith, D. C., Martinez, P., Han, S., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01160-z · Cited by 42
Panyard, D. J., Reus, L. M., Ali, M., Liu, J., Deming, Y. K., Lu, Q., Kollmorgen, G., Carboni, M., Wild, N., Visser, P. J., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13848 · Cited by 14
Self-citation
Metadata
- Authors
- Panyard, D. J., McKetney, J., Deming, Y. K., Morrow, A. R., Ennis, G. E., Jonaitis, E. M., Van Hulle, C. A., Yang, C., Sung, Y. J., Ali, M., Kollmorgen, G., Suridjan, I., Bayfield, A., Bendlin, B. B., Zetterberg, H., Blennow, K., Cruchaga, C., Carlsson, C. M., Johnson, S. C., Asthana, S., Coon, J. J., & Engelman, C. D.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2023-05-22
- Volume
- 19
- Issue
- 12
- Pages
- 5447-5470
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4377565297
- Cited by
- 44
- References
- 49
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- National Center for Advancing Translational Sciences (UL1TR000427)
- Wisconsin Alumni Research Foundation
- National Institute on Aging (R01AG27161, R01AG054047, R21AG067092, R01AG037639, R01AG021155, P50AG033514, P30AG062715, P30AG017266, T32AG000213, 1R01AG068398‐01, R01AG044546, R01AG064877, RF1AG053303, U01AG058922, R01AG064614, P30AG066444, P01AG003991, 1RF1AG074007, R01AG058501)
- European Research Council (#681712)
- National Institute of Child Health and Human Development (P2CHD047873)
- Hjärnfonden (#FO2019‐0228, #FO2017‐0243)
- National Heart, Lung, and Blood Institute (5T32HL83806)
- National Institute of General Medical Sciences (P41GM108538)
- U.S. National Library of Medicine (T32LM012413)
- Stiftelsen för Gamla Tjänarinnor (#SGT2021‐09‐Zetterberg)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.